LYEL
Lyell Immunopharma, Inc.
There isn't enough reported data to score LYEL yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
LYEL Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Under pressure | |
| Unavailable |
LYEL's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
LYEL PE Valuation
LYEL has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
LYEL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect LYEL's revenue to grow, with its earnings and profitability holding steady.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
LYEL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$12.32 | +$10.70 |
| Q2 2026 | -$12.59 | +$11.70 |
| Q1 2026 | -$13.56 | +$11.44 |
| Q4 2025 | -$16.06 | +$10.14 |
| Q3 2025 | -$23.02 | -$7.22 |
| Q2 2025 | -$24.29 | -$7.89 |
| Q1 2025 | -$25.00 | -$7.00 |
| Q4 2024 | -$26.20 | -$7.60 |
LYEL is still losing money, but far less than before: $12.32 per share over the past year, against $26.20 at its worst in late 2024.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over LYEL on earnings quality, reporting a profit while its opponent remains loss making.
LYEL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3K | -80% |
| Q2 2026 | $4K | -50% |
| Q1 2026 | $2K | -71% |
| Q4 2025 | $6K | -45% |
| Q3 2025 | $15K | -56% |
| Q2 2025 | $8K | -38% |
| Q1 2025 | $7K | +133% |
| Q4 2024 | $11K | -15% |
LYEL's revenue has slid since its 2022 peak: $3,000 last quarter, down 80% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1609833% | -1361480 points |
| Q2 2026 | -1183425% | -594175 points |
| Q1 2026 | -2213050% | -1393521 points |
| Q4 2025 | -2127400% | -298791 points |
| Q3 2025 | -248353% | -99809 points |
| Q2 2025 | -589250% | -192881 points |
| Q1 2025 | -819529% | +1032971 points |
| Q4 2024 | -1828609% | -1370855 points |
LYEL's operating margin was −1609833% last quarter, down 1361480 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over LYEL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over LYEL on profitability, with a higher operating margin.
LYEL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.6M | -$6M |
| Q2 2026 | -$34.2M | +$448K |
| Q1 2026 | -$38.6M | +$16.4M |
| Q4 2025 | -$32.6M | +$14.7M |
| Q3 2025 | -$28.6M | +$6.5M |
| Q2 2025 | -$34.6M | +$3.8M |
| Q1 2025 | -$55M | -$12.9M |
| Q4 2024 | -$47.3M | -$6.6M |
LYEL has burned cash in almost every quarter: −$140M over the past year, against −$166M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over LYEL on cash generation, producing positive trailing cash flow while its opponent burns cash.
LYEL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.6% | +1.1M shares |
| 1 year | +65% | +9.6M shares |
| 3 years | +95% | +11.9M shares |
| 5 years | +105% | +12.5M shares |
LYEL has 24M diluted shares, up 65% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | $11.8M |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over LYEL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
LYEL Net Leverage
LYEL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
LYEL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.4 | Neutral |
| Stochastic | 65.6 | Neutral |
LYEL's weekly RSI is 55 (neutral) and its Stochastic is 66 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
LYEL PE vs Healthcare Sector
LYEL has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
LYEL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.9 | 44% above |
| 20 week MA | $12.5 | 25% above |
| 50 week MA | $18.3 | 14% below |
| 100 week MA | $15.3 | 2.2% above |
| 200 week MA | $28.4 | 45% below |
LYEL has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
LYEL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $324.0 | $164.2 | -49% |
| 2022 | $164.2 | $61.0 | -63% |
| 2023 | $61.0 | $38.8 | -36% |
| 2024 | $38.8 | $13.0 | -66% |
| 2025 | $13.0 | $35.1 | +170% |
| 2026 YTD | $35.1 | $15.6 | -55% |
LYEL's yearly returns have swung widely, from +170% in 2025 to −66% in 2024. It's down 55% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over LYEL on returns for 2026, with the stronger performance.